Key Takeaways & Executive Findings
- ā¢ā¢ Non-porous microcarriers are essential for large-scale adherent cell culture in stirred-tank bioreactors, supporting cell densities of 10^9-10^10 cells/L. ⢠The material selection for non-porous microcarriers is driven by the need for appropriate surface charge or integrin binding sites to promote cell adhesion. ⢠Commercialized non-porous microcarriers are primarily made of dextran, polystyrene, and collagen, while chitosan and cellulose-based alternatives show promise but are not yet commercialized. ⢠Crosslinking is the predominant preparation method for non-porous microcarriers, with novel droplet dispersion systems potentially reducing production costs.
Abstract
BACKGROUND: The key consumable item in stirred-tank bioreactors is non-porous microcarriers, which are suitable for adherent cell culture and play a significant role in the fabrication of viruses, recombinant proteins, and stem cells. OBJECTIVE: To summarize the material selection and manufacturing methods of non-porous microcarriers based on the favorable conditions for cell-microcarrier adhesion. METHODS: A computerized search of CNKI, PubMed, and Web of Science databases was performed with the search terms ācell cultivation, adherent cells, microcarrier, fibronectin, bioreactor, microsphere preparationā in Chinese and ācell adhesion, microcarrier, bioreactor, dextran, cell-matrix interaction, suspension cultureā in English. The search time limit was from 1967 to 2025. After screening according to the inclusion and exclusion criteria, 52 articles were finally included for summary analysis. RESULTS AND CONCLUSION: Non-porous microcarriers are suitable for adherent cell culture at a density of 109-1010 cells/L. Due to the requirements for cell adhesion, non-porous microcarriers need to provide appropriate surface positive charge or integrin binding sites. Dextran, polystyrene, and collagen-based non-porous microcarriers have been commercialized and can widely support large-scale culture of various cells. Chitosan and cellulose-based non-porous microcarriers have been reported for large-scale cell culture, but these new materials have not been commercialized. Dextran and polystyrene microcarriers have been commercialized for a long time, with preparation methods of crosslinking and polymerization, respectively, and mature preparation technology. Collagen and cellulose microcarriers are mostly prepared by crosslinking, while chitosan microcarriers can be prepared by crosslinking and phase inversion.
1. Introduction
Cell culture in petri dishes with milliliter-scale medium volumes typically yields only a few million cells per dish, requiring manual operation for each dish. Due to low cell yield, high labor costs, and variability between dishes, this method is not suitable for applications such as virus production, recombinant protein extraction, or stem cell therapy.
For liter-scale cell culture, important applications include cultivating and lysing infected cells to extract viruses for vaccine manufacturing, purifying extracellular recombinant proteins and monoclonal antibodies, and producing stem cell drugs. Traditional cell factories use roller bottles with inner surface areas of 490-1,900 cm². To obtain 10^10 Vero cells (a continuous heteroploid cell line derived from African green monkey kidney epithelium, widely used in virus research and vaccine production), 100-400 roller bottles would be required, each needing inoculation, medium changes, nutrient monitoring, and passaging. This results in high labor costs and poor uniformity between bottles. In contrast, a single 5-10 L bioreactor can meet the demand for 10^10 Vero cells, offering batch processing advantages, lower labor costs, and better homogeneity of cell growth across carriers.
In 1967, Van Wezel first proposed a method to culture adherent cells on spherical microcarriers suspended by stirring, which became known as microcarrier technology. Over the years, this technology has been industrialized. Bioreactors keep microcarriers with attached cells suspended in medium via stirring or perfusion, allowing efficient nutrient access. Non-porous spherical microcarriers (referred to as microcarriers) are compatible with stirred-tank bioreactors and are used for adherent cell culture at densities of 10^9 cells/L [2-3].
Loading authentic research manuscript (Pages 1ā5)...
Sun Jingshan, Deng Jingqian, Qi Liya, Zhao Xiaohuan, Hou Dandan (2026). Material selection and manufacture method of non-porous adherent cell microcarriers. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21597
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are non-porous microcarriers used for?
Non-porous microcarriers are used in stirred-tank bioreactors for large-scale culture of adherent cells, such as Vero cells, for applications in virus production, recombinant protein manufacturing, and stem cell therapy.
What materials are commonly used for non-porous microcarriers?
Common materials include dextran, polystyrene, and collagen, which have been commercialized. Chitosan and cellulose are emerging materials with potential but are not yet commercially available.
What are the key requirements for non-porous microcarriers?
They must be non-cytotoxic, have a diameter of 100-400 μm, settle at a rate of 10-20 cm/min, and provide appropriate surface charge or integrin binding sites to promote cell adhesion.
What are the main preparation methods for non-porous microcarriers?
The main methods include crosslinking (used for dextran, collagen, cellulose, and chitosan) and polymerization (used for polystyrene). Novel droplet dispersion systems are being explored to reduce costs.
Why are non-porous microcarriers preferred over porous ones?
Non-porous microcarriers are preferred for certain applications because they provide a uniform surface for cell adhesion and growth, and they are compatible with stirred-tank bioreactors, allowing efficient scale-up.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.